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Abstract 
Importance. Statin intolerance due to muscle-related adverse effects is reported by 5-20% 
of patients and represents a challenging problem. 
Objective. To identify patients with muscle symptoms confirmed by statin rechallenge and 
compare lipid-lowering efficacy for 2 non-statin therapies, ezetimibe and evolocumab 
Design. 2-stage trial. Phase A used a 24-week crossover procedure with atorvastatin or 
placebo to identify patients with symptoms only with atorvastatin, but not placebo. In 
phase B, after a 2-week washout, patients were randomized to ezetimibe or evolocumab for 
24 weeks. 
Participants. 511 patients with uncontrolled low-density lipoprotein cholesterol (LDL-C) 
and history of intolerance to 2 or more statins at 53 centers in North America, Europe, 
Australia, and South Africa enrolled between December 10, 2013 and November 28, 2014. 
Interventions. Phase A: Atorvastatin 20 mg vs. placebo. Phase B: Randomization 2:1 to 
subcutaneous evolocumab 420 mg monthly or oral ezetimibe 10 mg daily.  
Main Outcome Measures. Co-primary endpoints were the mean percent change in LDL-C 
for the mean of weeks 22 and 24 and at week 24. Safety and tolerability of ezetimibe and 
evolocumab in statin-intolerant patients. 
Results. Of the 492 patients who entered phase A (age 60.7 [SD, 10.2] years; 246 [50.1%] 
women; 170 [34.6%] with coronary disease; entry mean LDL-C level, 212.3 [SD, 67.9] 
mg/dL), muscle symptoms occurred in 209/491 (42.6%) while taking atorvastatin, but not 
while taking placebo. Of these patients, 199 entered phase B along with 19 other patients 
who proceeded directly to phase B for muscle symptoms with creatine kinase > 10X upper 
limit of normal during statin treatment (Total N=218, with 73 randomized to ezetimibe and 
145 to evolocumab; with entry mean LDL-C level of 219.9 [SD, 72] mg/dL) For the mean of 
weeks 22 and 24, LDL-C for ezetimibe was 183.0 mg/dL (95% confidence interval [CI]), 
167.7 to 198.3), mean percent LDL-C change −16.7% (95% CI, −20.5 to −12.9), absolute 
change -31.0 mg/dL (95% CI, –38.4 to –23.5) and for evolocumab, 103.7 mg/dL (95% CI, 
92.6 to 114.8), percent change −54.5% (95% CI, −57.2 to −51.8), absolute change -106.8 
mg/dL (95% CI, –112.2 to −101.4), P <.001. LDL-C at week 24 for ezetimibe was 181.5 
mg/dL (95% CI, 165.3 to 197.6), percent change −16.7% (95% CI, −20.8 to −12.5) absolute 
change -31.2 mg/dL (95% CI, –39.2 to –23.3) and for evolocumab, 104.1 mg/dL (95% CI, 
92.5 to 115.6), percent change−52.8% (95% CI, −55.8 to −49.8) absolute change -102.9 
mg/dL (95% CI, −108.7 to −97.2), P < .001. For the mean of weeks 22 and 24, between-
groups difference in LDL-C was –37.8% (95% CI, –42.3 to –33.3), absolute difference –75.8 
mg/dL (95% CI, –84.7 to –67.0). For week 24, between groups difference in LDL-C was –
36.1% (95% CI –41.1 to –31.1) absolute difference –71.7 mg/dL (95% CI, –81.3 to –62.2).  
Muscle symptoms were reported in 28.8% of ezetimibe patients and 20.7% of evolocumab 
patients, P=0.18. Active study drug was stopped for muscle symptoms in 5/73 (6.8%) 
ezetimibe patients and 1/145 (0.7%) evolocumab patient. 
Conclusions and Relevance. Among patients with statin intolerance due to muscle-related 
adverse effects, the use of evolocumab compared with ezetimibe resulted in a significantly 
greater reduction in LDL-C after 24 weeks. Further studies are needed to assess long-term 
efficacy and safety.  
Trial Registration: clinicaltrials.gov NCT01984424 
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Administration of HMG-CoA reductase inhibitors (statins) to reduce low-density 
lipoprotein cholesterol (LDL-C) represents an essential component of contemporary 
strategies to reduce morbidity and mortality from atherosclerotic vascular disease.1 
However, a significant proportion of patients with clinical indications for statin treatment 
report inability to tolerate evidence-based doses, most commonly due to muscle-related 
adverse effects.2 These statin intolerant patients typically report muscle pain or weakness 
when treatment is initiated or dosage increased, and relief when the drug is discontinued 
or the dosage reduced. Although some patients with statin-associated muscle symptoms 
experience marked elevation in serum creatine kinase (CK) levels, most do not. Accordingly, 
diagnosis of this disorder remains largely subjective based upon the presence of patient-
reported symptoms.3  The incidence of similar symptoms in placebo-treated patients has 
resulted in skepticism about the true incidence of statin intolerance.  
Patients with muscle-related intolerance often refuse to take statins despite 
elevated LDL-C levels and a high risk of major cardiovascular events. Current management 
may include very low or intermittent administration of statins or use of ezetimibe, but 
these strategies seldom achieve the > 50% reduction recommended by current 
guidelines.1,4,5 Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors markedly 
lower LDL-C and have shown potential as an alternative therapy in patients who 
experience intolerable adverse effects during statin therapy.6-8 Currently available data 
suggest that muscle-related adverse effects are uncommon with PCSK9 inhibitors, even in 
patients with a history of such symptoms , but prior trials relied exclusively on medical 
history to document statin intolerance. The Goal Achievement after Utilizing an Anti-PCSK9 
Antibody in Statin Intolerant Subjects (GAUSS-3) trial was designed as a multi-stage 
randomized clinical trial to first identify patients with statin-induced muscle symptoms 
during a placebo-controlled statin rechallenge procedure and subsequently to compare the 
effectiveness and tolerability of 2 non-statin therapies—ezetimibe or evolocumab, a 
recently-approved PCSK9 inhibitor.  
METHODS 
Study Design 
The GAUSS-3 trial enrolled patients with elevated LDL-C levels unable to tolerate an 
effective dose of a statin due to muscle-related adverse effects. Local institutional review 
boards approved the study protocol and all patients provided written informed consent.  
The methods are described in greater detail in a design manuscript and the protocol, which 
is available as an on-line supplement.9 Briefly, the study had 2 phases: After an initial 4 
week washout period where any statins, ezetimibe or other lipid-lowering agents were 
discontinued, participants were enrolled in phase A, a double-blind, placebo-controlled 
crossover procedure to rechallenge patients with atorvastatin. Patients were randomly 
assigned in a 1:1 ratio to either atorvastatin 20 mg daily or matching placebo for the first 
10 weeks (period 1), then underwent a 2-week washout period, followed by crossover to 
the alternate therapy for a second 10-week period (period 2). Patients who experienced 
intolerable muscle symptoms during the first period did not complete the full 10 weeks of 
exposure, but entered a 2-week washout period before proceeding to period 2.  After 
completion of phase A, patients who experienced muscle-related adverse effects while 
taking atorvastatin, but not on placebo, were eligible for phase B, a 24-week double blind, 
randomization to ezetimibe or evolocumab using a double dummy design in which patients 
received either injectable placebo and oral ezetimibe or injectable evolocumab and oral 
placebo. Alternatively, patients could proceed directly to phase B if they had a documented 
history of CK elevation > 10 × upper limit of normal accompanied by muscle symptoms 
while on statin therapy with documented resolution of both CK elevation and symptoms 
upon discontinuation. These study procedures were designed to ensure that only patients 
with reproducible statin-associated muscle symptoms entered phase B of the study. For 
phase B, patients were randomized 2:1 to subcutaneously administered evolocumab 420 
mg monthly or oral ezetimibe 10 mg administered daily. Randomization for both phases 
was performed centrally via an interactive web-based or voice recognition system. In phase 
A, randomization used a permuted block size of 4. Phase B used a permuted block size of 3, 
with stratification for LDL-C (< 180 mg/dL vs. ≥ 180 mg/dL). Allocation was concealed 
using a centralized randomization process. Information on race was assessed by 
investigators and used to determine if outcomes were different for patients from different 
racial subgroups.   
Inclusion criteria 
The main eligibility criteria for phase A included male or female patients between 18 and 
80 years of age and inability to tolerate atorvastatin at 10 mg and any other statin at any 
dose or alternatively, ≥ 3 statins with 1 at the lowest average daily starting dose and 2 
other statins at any dose. The lowest average starting dose was defined as 5 mg 
rosuvastatin, 10 mg simvastatin, 40 mg pravastatin, 20 mg lovastatin, 40 mg fluvastatin, or 
2 mg pitavastatin. For patients with diagnosed coronary heart disease (CHD), lipid 
inclusion criteria required an LDL-C ≥ 100 mg/dL. Patients without CHD were required to 
have an LDL-C ≥ 130 mg/dL with ≥ 2 risk factors, ≥160 mg/dL with ≥ 1 risk factor, or 
≥ 190 mg/dL with no additional risk factors.  Patients were excluded for myocardial 
infarction, unstable angina, coronary revascularization, or stroke within 3 months before 
randomization.  Other inclusion and exclusion criteria are listed in the protocol available as 
an online supplement.  
Treatments 
Atorvastatin 20 mg tablets and matching placebo were supplied as over-encapsulated 
tablets. Evolocumab (140 mg) and matching placebo were supplied in a single use, 
disposable, handheld mechanical (spring-based) 1.0 mL prefilled autoinjector pen for 
subcutaneous administration. Patients were instructed to administer 3 autoinjector doses 
subcutaneously each month providing a 420 mg total dosage of evolocumab.  Ezetimibe 
10 mg tablets and matching placebo were supplied as over-encapsulated tablets for daily 
administration. 
Primary and Secondary Endpoints 
In phase B, to account for the pharmacodynamic effects of a PCSK9 antibody administered 
monthly (evolocumab), the study prespecified 2 co-primary endpoints: mean percent 
change from baseline in LDL-C for the mean of weeks 22 and 24, which approximates mean 
treatment effect, and a more conservative measure, the percent change from baseline in 
LDL-C at week 24, which reflects effects at the end of the dosing interval. Using the same 2 
time points, tier 1 co-secondary efficacy endpoints assessed absolute change from baseline 
in LDL-C, percent change from baseline in total cholesterol, non-high-density lipoprotein 
cholesterol (non-HDL-C), apolipoprotein B (ApoB), total cholesterol/HDL-C ratio, 
ApoB/apoliproteinA1 (ApoA1) ratio, and the percent of patients achieving an LDL-C < 70 
mg/dL. Tier 2 co-secondary efficacy endpoints were also measured as the mean of weeks 
22 and 24 and at week 24 and included lipoprotein(a), triglycerides, HDL-C, and very low-
density lipoprotein cholesterol (VLDL-C).  
The incidence of treatment emergent adverse events, serious adverse events, and 
adverse events leading to discontinuation of study drug were collected for each 
randomized treatment group. Prespecified safety and tolerability outcomes included the 
incidence of muscle-related adverse effects during phase A. Adverse events were coded 
using the current version of Medical Dictionary for Regulatory Activities. An independent 
committee adjudicated clinical events including death, myocardial infarction, 
hospitalization for unstable angina, coronary revascularization, stroke, transient ischemic 
attack, and hospitalization for heart failure. The incidence of anti-evolocumab antibodies 
(binding and neutralizing) at any time was assessed.  
Statistical Methods 
The analyses of safety and tolerability during the phase A double-blind statin rechallenge 
included all randomized participants who received ≥ 1 dose of atorvastatin or placebo. 
Efficacy and safety analyses for phase B included all randomized patients who received ≥ 1 
dose of ezetimibe or evolocumab. Baseline lipid values were defined as those taken at 
baseline for phase A for patients who participated in this phase or at baseline for phase B 
for patients who bypassed phase A. For the co-primary endpoints, a repeated measures 
linear effects model was used to compare the efficacy of evolocumab with ezetimibe, which 
included terms for treatment group, stratification by LDL-C (< 180 mg/dL vs. ≥ 180 mg/dL), 
scheduled visit and the interaction of treatment with scheduled visit. A positive result for 
the trial required statistical significance for both co-primary endpoints.  For efficacy 
endpoints, where the analysis method was the repeated measures linear effects model, 
missing lipid measurements not imputed. The statistical model for the co-secondary 
efficacy endpoints was identical to the co-primary endpoints with the exception of the 
endpoint percent of patients achieving LDL-C < 70 mg/dL, which was analyzed using the 
Cochran-Mantel Haenszel test adjusted by the LDL-C stratification. Multiplicity adjustments 
were applied for analyses of co-primary and co-secondary endpoints to control the overall 
familywise error rate at 0.05 using a combination of sequential testing, the Hochberg 
procedure, and the fallback procedure.10 The statistical approach for control of multiplicity 
is shown in the Supplemental Appendix (Figure 1). Cumulative incidence estimates were 
calculated using the Kaplan Meier method with hazard ratios calculated using an 
unstratified Cox model and P-values calculated using the log rank test. Analyses were 
performed using Statistical Analysis Software (SAS Institute; Cary, NC), version 9.3.  
Sample Size Determination 
The expected number of participants to be enrolled in phase A was 500 to provide 100 
patients for phase B, assuming a rate of 20% for muscle-related intolerance in phase A, 
which was a conservative estimate based on observational studies.3 The mean (95% CI) for 
LDL-C reduction for evolocumab compared with ezetimibe was estimated as –35.9%  
(95% CI, –44.1%, –27.8%) from prior studies.7,8 Assuming 15% of phase B randomized 
patients would end treatment early, but remain in the study, 5% would end the study early, 
and 2% would not receive any study drug, a sample size of 100 provided 98% power for 
each of the co-primary endpoints and 96% power to simultaneously detect significant 
treatment effects for the co-primary endpoints. The sample size calculation was performed 
using a 2-sided t-test with a 0.05 significance level, an attenuated treatment effect of 21% 
greater reduction in LDL-C with evolocumab and an attenuated common standard 
deviation (SD) of 24%.  
RESULTS 
Study Participants 
Study participants were enrolled between December 10, 2013 and November 28, 2014. 
The characteristics of patients during phases A and B were similar in both phases (Table 1). 
There were approximately equal numbers of men and women with a mean age of 
approximately 60 years. More than 80% of patients had a history of intolerance to ≥ 3 
statins before entering the study. CHD was present in approximately one-third of patients, 
hypertension in more than half, and the majority were classified in the National Cholesterol 
Education Program (NCEP) high-risk category.11 Mean LDL-C levels were 212.3 mg/dL (SD, 
67.9) for all patients entering phase A, and 219.9 mg/dL (SD, 72.0) for all patients who 
participated in phase B of the trial.  
Statin Rechallenge Outcomes 
The disposition of patients in the trial is shown in Figure 1. A total of 492 patients entered 
phase A, the statin rechallenge procedure, with 491 receiving ≥ 1 dose of study drug, 245 of 
whom received atorvastatin before placebo and 246 of whom received placebo before 
atorvastatin. For those receiving atorvastatin first, 126 (51.4%) developed a muscle 
adverse event on atorvastatin, but not placebo, 122 (49.8%) completed phase A, and 120 
(49%) proceeded to phase B. For those receiving placebo first, 83 (33.7%) developed a 
muscle adverse event on atorvastatin, but not placebo, 80 (32.5%) completed phase A and 
79 (32.1%) proceeded to phase B. Overall, 209/491 patients (42.6%) with a history of 
muscle-related adverse effects reported intolerable symptoms in phase A when subjected 
to a double-blind, placebo-controlled atorvastatin rechallenge of whom 199 entered phase 
B. Conversely, 130 (26.5%) of the participants experienced intolerable muscle symptoms 
on placebo, but not atorvastatin during phase A. The numbers and percentages of patients 
experiencing a muscle-related adverse effect on atorvastatin, placebo, neither, or both 
treatments during phase A are shown in Table 2 categorized by first treatment received.   
The time to first muscle-related adverse effect is shown in Figures 2 for patients who 
received ≥ 1 dose of study drug during phase A.  Figure 2A shows the time to muscle-
related adverse effect for patients randomized to atorvastatin or placebo during the first 
10-week period and Figure 2B shows this outcome for patients randomized to atorvastatin 
or placebo during the second 10-week period. During the first period, the hazard ratio (HR) 
for developing muscle symptoms for atorvastatin compared with placebo was 1.34 (95% 
confidence intervals [CI], 1.05 to 1.71), P=0.02 (Figure 2A). During the second period, the 
hazard ratio (HR) for developing muscle symptoms for atorvastatin compared with placebo 
was 1.96 (95% CI, 1.44 to 2.66), P<0.001 (Figure 2B). Nineteen patients bypassed phase A 
due to myalgia with a documented 10-fold increase in CK during statin administration. A 
total of 218 patients entered phase B and received ≥ 1 dose of study drug, 73 of whom were 
randomized to ezetimibe plus subcutaneous placebo and 145 were randomized to 
evolocumab plus oral placebo. 
Efficacy Endpoints 
The primary and secondary efficacy endpoints are shown numerically in Table 3. The effect 
of ezetimibe and evolocumab on LDL-C during the phase B is displayed graphically in 
Figure 3.  Lipid values were unavailable at 24 weeks for 16 patients in the ezetimibe group 
and 28 patients in the evolocumab group. For the co-primary endpoint, for the mean of 
weeks 22 and 24, LDL-C was 183.0 mg/dL (95% CI, 167.7 to 198.3), the least squares (LS) 
mean percent change from baseline −16.7% (95% CI, −20.5 to −12.9) for ezetimibe and 
103.7 mg/dL (95% CI, 92.6 to 114.8), mean percent change, −54.5% (95% CI, −57.2 to 
−51.8) for evolocumab, a mean difference of –37.8% (95% CI, –42.3 to –33.3) P < .001. For 
the other co-primary endpoint, LDL-C at week 24 was 181.5 mg/dL (95% C I, 165.3 to 
197.6), the LS mean percent change from baseline −16.7% (95% CI, −20.8 to −12.5) for 
ezetimibe and 104.1 mg/dL (95% CI, 92.5 to 115.6), mean percent change, −52.8% (95% CI, 
−55.8 to −49.8) for evolocumab, a mean difference of -36.1% (95% CI –41.1 to –31.1) P 
< .001. Secondary endpoints including percent changes in total cholesterol, non-HDL-C, 
ApoB, total cholesterol/HDL-C ratio, and ApoB/ApoA1 ratio showed similar results. 
The co-secondary endpoint, absolute change in LDL-C for the mean of weeks 22 and 24 
showed LS mean change of −31.0 mg/dL (95% CI, −38.4 to −23.5) for ezetimibe and −106.8 
mg/dL (95% CI, –112.2 to −101.4) for evolocumab, a mean difference of –75.8 mg/dL (95% 
CI, –84.7 to –67.0). P < .001. The other co-secondary endpoint, absolute change in LDL-C at 
week 24, showed LS mean change of −31.2 mg/dL (95% CI, −39.2 to −23.3) for ezetimibe 
and −102.9 mg/dL (95% CI, −108.7 to −97.2) for evolocumab, a mean difference of –71.7 
mg/dL (95% CI, –81.3 to -62.2).  P < .001. Mean changes for Lp(a) with ezetimibe were 
−1.6% (95% CI, −7.2 to 3.9) for the mean of weeks 22 and 24 and 0.2 (95% CI, −5.8 to 6.2) 
at week 24 and with evolocumab at the same time points, −22.7% (95% CI, −26.7 to −18.7) 
and −21.1% (95% CI, −25.4 to −16.7), respectively, P < .001. Between group differences 
were -21.1% (95% CI, –27.7 to –14.5) for the mean of 22 and 24 weeks and –21.2% (95% 
CI, –28.4 to –14.1) at week 24.  For the mean of weeks 22 and 24, 1.4% (95% CI, 0.3 to 7.7) 
of patients achieved an LDL-C < 70 mg/dL with ezetimibe and 29.9% (95% CI, 22.9 to 38.1) 
with evolocumab, P < .001. At week 24, 0% (95% CI, 0.0 to 6.3) of patients achieved an 
LDL-C < 70 mg/dL with ezetimibe and 27.4% (95%, 20.1 to 36.1) with evolocumab, P 
< .001.  
Safety and Tolerability Outcomes 
During phase B, any muscle-related adverse event occurred in 21 ezetimibe-treated 
patients (28.8%) and 30 evolocumab-treated patients (20.7%). (Table 4) Supplemental 
Figure 2 shows non-prespecified analyses of the time to patient-reported muscle 
symptoms for evolocumab compared with ezetimibe, HR 0.68 (95% CI, 0.39 to 1.19), 
P=0.17. Muscle symptoms leading to discontinuation of oral study drug occurred in 5/73 
(6.8%) ezetimibe-treated patients and 11/145 (7.6%) evolocumab-treated patients 
receiving oral placebo. Muscle symptoms leading to discontinuation of injectable study 
drug occurred in 1/145 (0.7%) evolocumab-treated and 0/73 ezetimibe-treated patients 
receiving placebo injections. (Table 4) Any investigator-reported increase in CK occurred in 
1 ezetimibe-treated patient (1.4%) and 4 evolocumab-treated patients (2.8%). Injection 
site reactions occurred in 2/73 (2.7%) patients treated with subcutaneous placebo and 
7/143 (4.8%) evolocumab-treated patients. There were 2 adjudicated major adverse 
cardiovascular events in the trial: 1 myocardial infarction in each treatment group and no 
deaths in either group. Evolocumab-binding antibodies developed in 1 patient (0.7%) and 
no neutralizing antibodies in any patient. Other common adverse effects are shown in 
Table 4. 
DISCUSSION 
Statin intolerance due to muscle symptoms represents a major unresolved challenge to the 
delivery of optimal cardiovascular care. The reported incidence of statin-associated muscle 
symptoms in observational studies ranges from 5%-29% of treated patients, varying by 
statin and dose.2  Often, despite multiple attempts to find a statin regimen acceptable to the 
patient, practitioners resort to less effective therapies. Alternative approaches typically 
include use of ezetimibe or administering statins intermittently or at dosages below the 
approved starting dose.4.5.12 These alternative therapeutic strategies provide less LDL-C 
reduction than recommended by current practice guidelines and result in higher LDL-C 
levels than most practitioners consider acceptable for optimal reduction of cardiovascular 
risk. The problem of statin-associated muscle symptoms is particularly vexing for patients 
with known cardiovascular disease (ie, secondary prevention) or those with very high LDL-
C levels (eg, patients with heterozygous familial hyperlipidemia). However, concerns exist 
about the ability to reliably diagnose this disorder, uncertainty about its true incidence, and 
absence of clinical outcome data for non-statin therapies.  
In the current trial, we sought to address several of these concerns, first by 
determining the incidence of statin intolerance due to muscle-related adverse effects with a 
blinded atorvastatin rechallenge and subsequently, by evaluating the tolerability and 
relative efficacy of 2 potentially useful therapies in these patients, ezetimibe and a recently-
approved PCSK9 inhibitor, evolocumab. To identify the presence of statin intolerance, the 
trial design employed a 2-staged approach previously tested in a smaller study.13 In the 
first phase of the study, patients with a strong history of muscle-related statin intolerance 
were administered both atorvastatin and placebo using a crossover procedure to allow 
identification of patients who developed muscle symptoms during atorvastatin 
administration, but not during placebo treatment. During this rechallenge procedure, we 
observed a 42.6% rate of discontinuation for intolerable muscle symptoms on atorvastatin, 
but not placebo, which was modestly higher than reported in a smaller prior study using 
simvastatin.13 However, 26.5% of patients reported similar symptoms on placebo, but not 
atorvastatin, demonstrating that reported muscle symptoms are not always related to 
statin use. Since statin-associated muscle symptoms are dose-related, the rate observed in 
GAUSS-3 for atorvastatin 20 mg may underestimate the problem, particularly for patients 
needing high intensity statin therapy such as those enrolled in the trial.  
During the second phase of the trial, patients with reproducible statin-induced muscle 
symptoms during rechallenge were randomized to 2 non-statin LDL-C lowering therapies 
to assess both efficacy and tolerability. The PCSK9 inhibitor evolocumab produced 
significantly larger reductions in LDL-C and other atherogenic lipoproteins (Table 3 and 
Figure 3). Both co-primary endpoints showed a 16.7% reduction for ezetimibe and a > 50% 
reduction with evolocumab. These reductions in LDL-C are consistent with current labeling 
for both products. Despite very high baseline values, the LDL-C goal of < 70 mg/dL was 
achieved in 1.4% of ezetimibe-treated patients and nearly 30% of patients administered 
evolocumab (Table 3). The LDL-C reduction for both drugs was stable by 4 weeks and 
sustained during the course of the 24 weeks of treatment (Figure 3).  
The study also clearly demonstrates the unmet medical need in this population, all of 
whom had either pre-existing CV disease or multiple risk factors and very high baseline 
LDL-C, which on average exceeded 210 mg/dL. In such patients, LDL-C reduction with 
statins is considered a particularly important priority in efforts to prevent cardiovascular 
morbidity and mortality. Because some patients cannot tolerate statins, the need for 
alternative LDL-C lowering strategies in such patients is self-evident. Previous trials have 
suggested that PCSK9 inhibitors are effective at lowering LDL-C and well tolerated by 
patients with a history of statin-associated muscle symptoms.6-8 Although these initial trials 
included some patients with a history of extreme CK elevations during statin treatment, the 
studies did not employ a placebo-controlled statin rechallenge procedure to identify the 
presence of statin intolerance. In retrospect, these studies may have included many 
patients who would have been able to tolerate 10 weeks of atorvastatin 20 mg during 
blinded rechallenge.  
Both ezetimibe and evolocumab were well tolerated during the trial, with 5 ezetimibe 
patients (6.8%) and 1 evolocumab patient (0.7%) discontinuing active treatment due to 
muscle-related adverse events. However, 11 evolocumab-treated patients (7.6%) 
discontinued oral placebo for muscle symptoms.  These findings demonstrate that both 
drugs are unlikely to provoke muscle symptoms and can be administered successfully in 
such patients, although with significant differences in lipid-lowering efficacy. Since a 
minority of patients achieved optimal LDL-C levels despite treatment with evolocumab, it 
may be worth exploring the addition of ezetimibe to evolocumab for those patients 
requiring further LDL-C reduction. It should be noted that neither ezetimibe nor 
evolocumab is approved for reduction in major adverse cardiovascular events. Although a 
single outcome trial was completed for ezetimibe and showed modest event reduction, the 
drug was not approved for a clinical outcome benefit.14 Evolocumab and other PCSK9 
inhibitors are undergoing study in large clinical outcomes trials that are expected to 
complete starting in 2016 or 2017.15-17 
The GAUSS-3 trial represents the largest and most comprehensive study using a 
blinded rechallenge procedure to assess the ability of patients with a history of muscle-
related adverse effects to tolerate statins.  The trial provides insights into the time course 
of statin-associated muscle-related adverse effects. As shown in Figure 2A, initial 
randomization to either atorvastatin or placebo in phase A resulted in similar rates of 
muscle symptoms during the first 50 days with a modest increase in the occurrence for 
atorvastatin near the end of the 10 week exposure, HR 1.34 (95% CI, 1.05 to 1.71), P=0.02. 
After crossover to period B, shown in Figure 2B, larger numbers of patients experienced 
symptoms in the atorvastatin treatment group, with differences in event rates occurring 
relatively early, HR 1.96 (95% CI, 1.44 to 2.66), P<0.001. Study participants were aware 
that they might receive a statin during Phase A and frequently reported intolerable muscle 
symptoms while receiving placebo, clearly demonstrating the importance on patient 
perceptions on inability to tolerate statins.  Although the reported rate of intolerance 
during atorvastatin administration was higher than observed with placebo, these 
differences were modest, reflecting the importance of the “nocebo effect” (adverse effects 
during placebo administration) in patients with a history of statin intolerance.18  
Our study has important limitations. Although larger than anticipated, the study was 
modest in size, reflecting the clinical challenges of requesting that participants with a 
strong history of muscle intolerance to undergo rechallenge with atorvastatin after 
experiencing unpleasant adverse effects during prior attempts at statin treatment. The 
study design also did not permit the use of a common management strategy for patients 
with muscle-related symptoms, administration of small doses of statins 1-3 times weekly. 
However, such a study design would be very challenging, since this approach often requires 
months of careful titration to reach the highest statin dosage that is tolerable to individual 
patients.  The 24-week duration of therapy was relatively short in patients who require 
lifetime LDL-C reduction. However, the majority of patients report statin-associated muscle 
adverse effects within the first 3 months of initiating therapy.  An additional limitation is 
that many of these patients with very high baseline LDL-C levels did not achieve optimal 
LDL-C levels and would require additional agents, which may be associated with muscle 
symptoms. Although preliminary data are promising, definitive data on cardiovascular 
outcomes with evolocumab are not yet available.19 
CONCLUSIONS 
Among patients with statin intolerance due to muscle-related adverse effects, the use 
of evolocumab compared with ezetimibe resulted in a significantly greater reduction in 
LDL-C after 24 weeks. Further studies are needed to assess long-term efficacy and safety.   
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Table 1. Baseline Demographics and Laboratory Values 
 Phase A Phase B 
 
All Randomized 
 
Assigned 
atorvastatin 
followed by 
placebo 
Assigned  
placebo 
followed by 
atorvastatin 
Total 
qualifying 
for phase B 
Randomized 
to Ezetimibe 
 
Randomized 
to 
Evolocumab  
 N = 491
a
 N = 245
a
 N = 246 N=218 N = 73 N = 145 
Gender, n (%)      
Female 246 (50.1)  120 (49.0)    126 (51.2) 106 (48.6) 39 (53.4) 67 (46.2) 
Male 245 (49.9) 125 (51.0) 120 (48.8) 112 (51.4) 34 (46.6) 78 (53.8) 
Age, years, mean (SD)  60.7 (10.2) 61.5 (10.2) 59.9 (10.2) 58.8 (10.5) 58.5 (9.4) 59.0 (11.1) 
Race, n (%)      
White 465 (94.7) 231 (94.3) 234 (95.1) 207 (95.0) 69 (94.5) 138 (95.2) 
Other 26 (5.3) 14 (5.7) 12 (4.9) 11 (5.0) 4 (5.5) 7 (4.8) 
BMI, kg/m
2
, mean (SD) 28.5 (5.7) 28.4 (6.1) 28.5 (5.4) 28.0 (5.0) 28.5 (5.9) 27.8 (4.4) 
Coronary heart disease, n (%) 170 (34.6) 85 (34.7) 85 (34.6) 69 (31.7) 21 (28.8) 48 (33.1) 
Cerebrovascular disease or PAD, n (%) 113 (23.0) 59 (24.1) 54 (22.0) 44 (20.2) 17 (23.3) 27 (18.6) 
Cardiovascular risk factors, n (%) 
Current cigarette use 51 (10.4) 22 (9.0) 29 (11.8) 29 (13.3) 13 (17.8) 16 (11.0) 
Type 2 diabetes mellitus 63 (12.8) 29 (11.8) 34 (13.8) 26 (11.9) 10 (13.7) 16 (11.0) 
Hypertension 282 (57.4) 147 (60.0) 135 (54.9) 112 (51.4) 43 (58.9) 69 (47.6) 
Family history of premature CHD 190 (38.7) 91 (37.1) 99 (40.2) 86 (39.4) 32 (43.8) 54 (37.2) 
Low HDL-C 179 (36.5) 92 (37.6) 87 (35.4) 81 (37.2) 33 (45.2) 48 (33.1) 
Patients with 2 or more risk factors 236 (48.1) 119 (48.6) 117 (47.6) 104 (47.7) 44 (60.3) 60 (41.4) 
NCEP risk categories
b
, n (%) 
High risk 307 (62.5) 155 (63.3) 152 (61.8) 122 (56.0) 38 (52.1) 84 (57.9) 
Moderately high risk 54 (11.0) 26 (10.6) 28 (11.4) 29 (13.3) 8 (11.0) 21 (14.5) 
Moderate risk 73 (14.9) 40 (16.3) 33 (13.4) 38 (17.4) 16 (21.9) 22 (15.2) 
Lower risk 57 (11.6) 24 (9.8) 33 (13.4) 29 (13.3) 11 (15.1) 18 (12.4) 
History of intolerance to statins, n (%)  
 BMI, body mass index; NCEP, National Cholesterol Education Program; VLDL-C, very low-density lipoprotein cholesterol; HDL-C, high-density 
lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; PAD, 
peripheral arterial disease; TC, total cholesterol; ApoB, Apolipoprotein B; ApoA1, Apolipoprotein A1. aDoes not include one patient who never 
received study drug. bHigh risk is defined as coronary heart disease or a 10-year Framingham risk of > 20%, moderate risk as ≥ 2 
cardiovascular risk factors (10%-20% Framingham risk), and low risk as 1 or no cardiovascular risk factors *median (Q1, Q3)
1 statin 0 0 0 6 (2.8) 1 (1.4) 5 (3.4) 
2 statins 91 (18.5) 43 (17.6) 48 (19.5) 33 (15.1) 12 (16.4) 21 (14.5) 
3 statins or more statins 400 (81.5) 202 (82.4) 198 (80.5) 179 (82.1) 60 (82.2) 119 (82.1) 
Worst muscle-related side effect, n (%) 
Myalgia 410 (83.5) 203 (82.9) 207 (84.1) 173 (79.4) 61 (83.6) 112 (77.2) 
Myositis 79 (16.1) 41 (16.7) 38 (15.4) 31 (14.2) 7 (9.6) 24 (16.6) 
Rhabdomyolysis 2 (0.4) 1 (0.4) 1 (0.4) 14 (6.4) 5 (6.8) 9 (6.2) 
Baseline laboratory values, mean (SD) 
TC, mg/dL 300.5 (71.2) 300.0 (75.3) 301.0 (67.0) 307.0 (74.7) 308.0 (73.8) 306.5 (75.4) 
LDL-C, mg/dL 212.3 (67.9) 212.0 (72.2) 212.7 (63.6) 219.9 (72.0) 221.9 (70.2) 218.8 (73.1) 
HDL-C, mg/dL 50.9 (15.7) 51.0 (16.3) 50.9 (15.1) 49.8 (15.4) 50.2 (15.5) 49.7 (15.4) 
VLDL-C 36.4 (15.3) 36.5 (15.5) 36.3 (15.0) 36.7 (15.1) 35.7 (14.3) 37.1 (15.6) 
Non-HDL-C 249.6 (71.1) 249.0 (74.7) 250.2 (67.3) 257.2 (74.5) 257.8 (76.3) 256.9 (73.8) 
Apolipoprotein B 154.3 (40.4) 154.5 (44.1) 154.2 (36.5) 157.2 (41.7) 155.0 (42.4) 158.3 (41.5) 
TC/HDL-C ratio 6.4 (2.3) 6.4 (2.3) 6.4(2.3) 6.7 (2.5) 6.7 (2.7) 6.67 (2.4) 
ApoB/ApoA1 ratio 1.03 (0.34) 1.03 (0.36) 1.04 (0.33) 1.06(0.37) 1.06 (0.42) 1.06 (0.34) 
Triglycerides, mg/dL * 
170.0 
(121.5, 231.0) 
168.5 
(118.5, 228.5) 
172.8 
(123.5, 231.5) 
171.3 
(127, 233) 
162.5 
(127, 231) 
176.0 
(128, 233.5) 
Lipoprotein(a), nmol/L * 32.0 (15, 146) 33.5 (15, 156.5) 28.0 (14, 144) 31.0 (15, 156) 38.0 (18, 164) 29 (12.5, 152.5) 
hsCRP, mg/L * 1.6 (0.8, 3.4) 1.4 (0.8, 2.8) 1.7 (0.9, 4.1) 1.7 (0.9, 3.6) 1.7 (0.9, 3.8) 1.7 (0.9, 3.6) 
Table 2. Patients Experiencing Intolerable Muscle-Related Symptoms during Phase A 
 
Category, no. (%) 
Atorvastatin followed 
by placebo 
N=245 
Placebo followed 
by Atovastatin 
N=246 
All randomized 
patients 
N=491 
Symptoms on atorvastatin, but not placebo 126 (51.4) 83 (33.7) 209 (42.6) 
Symptoms on placebo, but not atorvastatin 42 (17.1) 88 (35.8) 130 (26.5) 
Symptoms on both placebo and atorvastatin 22 (9.0) 26 (10.6) 48 (9.8) 
No Symptoms on either treatment 47 (19.2) 38 (15.4) 85 (17.3) 
Did not complete phase A 8 (3.3) 11 (4.5) 19 (3.9) 
Did not participate in phase A (N=20) 
Bypassed Phase A due to CK elevation ≥ 10 x ULN NA NA 19  
Never received study drug NA NA 1 
ULN= upper limit of normal 
 
Table 3. Co-Primary and Secondary Efficacy Measures at 2 Time Points (24 weeks and mean of 22 and 24 weeks) 
Co-Primary Endpoints 
 Ezetimibe 
(n=73) 
Evolocumab 
(n=145) 
Adjusted 
P valueb 
LS Mean* 
difference 
95% CI 
 
 LS 
mean* 
95% 
CI 
  LS  
mean* 
95% 
CI 
   
Mean percent change in LDL-C 
    Mean for weeks 22 and 24  -16.7% -20.5,-12.9  -54.5% -57.2,-51.8 
<.001 
-37.8 -42.3, -33.3 
    At week 24  -16.7% -20.8,-12.5 -52.8% -55.8,-49.8 -36.1 -41.1, -31.1 
Tier 1 Co-Secondary Efficacy Endpoints 
Mean absolute change in LDL-C (mg/dL) 
    Mean for weeks 22 and 24  -31.0 -38.4, -23.5  -106.8 -112.2,-101.4 
<.001 
-75.8 -84.7, -67.0 
    At week 24  -31.2 -39.2, -23.3 -102.9 -108.7, -97.2 -71.7 -81.3, -62.2 
Mean percent change in mean total cholesterol 
    Mean for weeks 22 and 24  -11.4% -14.2, -8.7  -38.0% -40.1,-36.0 
<.001 
-26.6 -30.0, -23.3 
    At week 24  -11.6% -14.6, -8.6 -36.6% -38.8,-34.5 -25.1 -28.7, -21.5 
Mean percent change in mean non-HDL-C 
    Mean for weeks 22 and 24  -14.4% -17.8, -11.0  -47.4% -49.9,-45.0 
<.001 
-33.1 -37.1, -29.0 
    At week 24  -14.6% -18.2, -11.0 -45.7% -48.3, -43.1 -31.1 -35.4, -26.8 
Mean percent change in mean ApoB 
    Mean for weeks 22 and 24  -11.4% -15.0, -7.8  -45.3% -47.9, -42.7 
<.001 
-33.9 -38.2, -29.6 
    At week 24  -11.7% -15.6, -7.9 -43.5% -46.3, -40.7 -31.8 -36.4, -27.2 
Mean percent change in mean total cholesterol/HDL-C ratio 
    Mean for weeks 22 and 24  -11.5% -14.9, -8.0  -41.4% -43.9, -38.9 
<.001 
-29.9 -34.1, -25.8 
    At week 24  -12.8% -16.5, -9.2 -40.0% -42.7, -37.4 -27.2 -31.6, -22.8 
Mean percent change from baseline in ApoB/ApoA1 ratio 
    Mean for weeks 22 and 24  -11.9% -15.6, -8.1  -46.0% -48.7, -43.3 
<.001 
-34.1 -38.6, -29.7 
    At week 24  -12.6% -16.5, -8.7 -44.6% -47.4, -41.8 -32.0 -36.6, -27.3 
  N (%) 95% CI†  N (%) 95% CI†  
Patients achieving mean LDL-C < 70 mg/dL – n (%) 
    Mean for weeks 22 and 24  1 (1.4) 0.3, 7.7  
 
41 (29.9) 22.9, 38.1 
<.001 
28.5  19.1, 36.7 
    At week 24  0 (0) 0.0, 6.3 32 (27.4) 20.1, 36.1 27.4 17.3, 36.1 
Tier 2 Co-Secondary Efficacy Endpoints 
  LS mean* 95% CI  LS mean* 95% CI P value  
Mean percent change in mean Lipoprotein(a) 
    Mean for weeks 22 and 24  -1.6% -7.2, 3.9 )
a 
-22.7% -26.7, -18.7 
<.001 
-21.1 -27.7, -14.5 
    At week 24  0.2% -5.8, 6.2 -21.1% -25.4, -16.7 -21.2 -28.4, -14.1 
Mean percent change in mean triglycerides 
    Mean for weeks 22 and 24  -1.0% -8.7, 6.8 a -5.4 -11.0, 0.20  
0.37 
-4.4 -13.7, 4.9 
    At week 24  -1.1% -10.9, 8.7 -2.9 -9.9, 4.1 -1.8 -13.6, 10.0 
 Mean percent change in mean HDL-C 
    Mean for weeks 22 and 24  1.7% -1.7, 5.0  7.9% 5.4, 10.3 
0.008 
6.2 2.2, 10.2 
    At week 24  2.9% -0.8, 6.6 7.4% 4.7,10.1 4.5 0.0, 9.0 
Mean percent change in mean VLDL-C 
    Mean for weeks 22 and 24  -2.2% -8.5, 4.2  -6.8% -11.4, -2.2 
0.37 
-4.7  -12.3, 2.9 
    At week 24  -2.7% -10.3, 5.0 -3.9% -9.4, 1.6 -1.2 -10.5, 8.0 
*Least squares mean from repeated measures model which includes treatment group, 
b
Testing of each co-endpoint pair results in a single p-value, and for 
co-secondary endpoints these p-values are used in the Hochberg procedure. LDL-C stratification, scheduled visit and the interaction of treatment with 
scheduled visit as covariates. CI= confidence interval. LS= least squares LDL-C = Low Density Lipoprotein Cholesterol. VLDL-C=very low-density 
lipoprotein cholesterol. HDL-C= High Density Lipoprotein Cholesterol. ApoB= Apolipoprotein B. ApoA1=Apolipoprotein A1 
Table 4. Most Common Adverse Events during Phase B of the GAUSS-3 Trial  
Adverse Event 
Ezetimibe (n=73) 
Number of Patients 
(%) 
Evolocumab (n=145) 
Number of Patients 
(%) 
Total muscle-related events 21 (28.8) 30 (20.7) 
Myalgia 16 (21.9) 20 (13.8) 
Creatine kinase increase* 1 (1.4) 4 (2.8) 
Musculoskeletal pain 1 (1.4) 5 (3.4) 
Muscle weakness 0 (0) 3 (2.1) 
Nasopharyngitis 2 (2.7) 14 (9.7) 
Arthralgia 1 (1.4) 13 (9.0) 
Pain in extremity 1 (1.4) 13 (9.0) 
Muscle spasms 5 (6.8) 13 (9.0) 
Fatigue 5 (6.8) 12 (8.3) 
Headache 7 (9.6) 10 (6.9) 
Back pain 6 (8.2) 10 (6.9) 
Injection site reactions 2 (2.7) 7 (4.8) 
Influenza 1 (1.4) 7 (4.8) 
Diarrhea 4 (5.5) 6 (4.1) 
Urinary tract infection 4 (5.5) 5 (3.4) 
Nausea 3 (4.1) 5 (3.4) 
Rash 3 (4.1) 5 (3.4) 
Fall 1 (1.4) 5 (3.4) 
Gastrooesophageal reflux disease 0 (0.0) 5 (3.4) 
Insomnia 0 (0.0) 5 (3.4) 
Discontinuation of Treatment for Any Reason 
Discontinued oral drug treatment  14 (19.2) 23 (15.9) 
Discontinued subcutaneous drug treatment 4 (5.5) 7 (4.8) 
Discontinuation of Treatment for Muscle Symptoms 
Discontinued oral drug treatment  5 (6.8) 11 (7.6) 
Discontinued subcutaneous drug treatment 0 (0) 1 (0.7) 
Adjudicated Cardiovascular Events 
Myocardial infarction 1 (1.4) 1 (0.7) 
Percutaneous coronary intervention 2 (2.7) 3 (2.1) 
* Any investigator-reported elevation above upper limit of normal 
Figure	1.	Flow	of	Pa ents	During	the	GAUSS-3	Trial	
597 patients screened	
Phase A - Period 1 (atorvastatin) 
246 randomized to atorvastatin followed by placebo  
1 never received atorvastatin  
2 discontinued due to non-muscle adverse event 
2 discontinued at patients request 
1 lost to follow up 
73 randomized to ezetimibe and SC placebo	
4 discontinued subcutaneous placebo	
  1 due to non-muscle-related adverse event	
 3 at patient’s request	
14 discontinued oral ezetimibe	
5 due to muscle-related side effect	
7 due to non-muscle-related adverse effect	
2 at patient’s request	
3 discontinued study at patient’s request	
73 contributed to safety and efficacy analyses	
 	
145 randomized to evolocumab and oral placebo	
7 discontinued evolocumab	
4 due to non-muscle-related adverse event 
1 due to muscle-related side effect	
1 due to physician decision	
1 patient was lost to follow up	
23 discontinued oral placebo	
11 due to non-muscle-related adverse effect	
11 due to muscle-related side effect	
1 due to physician decision	
7 discontinued from study	
5 at patient’s request	
1 sponsor decision	
1 lost to follow up	
145 contributed to safety and efficacy analyses	
2 week washout	 2 week washout	
19 bypassed Phase A due to muscle symptoms with 10x increase 
in creatine kinase with resolution of symptoms and CK elevation 
with discontinuation of the statin 
Phase A - Period 1 (placebo) 
246 randomized to placebo followed by atorvastatin 
2 discontinued due to non-muscle adverse event 
4 discontinued at patient request 
1 discontinued per physician decision 
1 lost to follow-up 
4 week washout 
  86 patients excluded 
     36 did not meet inclusion criteria 
         16 due to LDL-C levels 
          12 for triglycerides <400 mg/dL 
           8 other reasons 
     34 did not meet exclusion criteria 
          5 for diabetes 
          4 for a cardiovascular event 
          25 for other reasons 
     16 met criteria but did not enroll 	511 eligible for Phase A 
    492 randomized to Phase A 
    19 bypassed Phase A 
218 randomized in Phase B	
 
Phase A - Period 2 (placebo)	
9 never received placebo 
237 received placebo	
1 discontinued due to non-muscle adverse event	
1 discontinued at patient request	
1 discontinued per sponsor decision	
126 developed a muscle-related adverse effect	
on atorvastatin, but not placebo 	
122 completed Phase A	
    120 proceeded to Phase B  
     2 did not proceed to Phase B for unknown reasons 
245 contributed to analysis of Phase A 
	
Phase A - Period 2 (atorvastatin)	
11 never received atorvastatin 
235 received atorvastatin 
1 discontinued due to other reason	
83 developed a muscle-related adverse effect	
on atorvastatin, but not on placebo	
80 completed Phase A 
    79 proceeded to Phase B 
    1 did not proceed to Phase B for unknown reasons 
246 contributed to analysis of Phase A 
	
 
 
 
